Regulus names Stelios Papadopoulos as chairman
pharmafile | June 12, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â Alnylam, Exelixis, RegulasÂ
Biopharma firm Regulas Therapeutics has named Stelios Papadopoulos chairman of its Board of directors.
Papadopoulos assumes the role from John Maraganore, who will remain a member of the Board. Papadopoulos, who has been on the Board since 2008, has more than 30 years of experience in the biotech and pharma industries as an investment banker, Board member, company founder and investor.
Papadopoulos is also a Board member of several companies including Biogen Idec, and Exelixis where he is also chairman.
“Stelios brings together financial savvy, business ingenuity and scientific creativity,” said John Maraganore, president and chief executive of Alnylam Pharmaceuticals. “I couldn’t think of a more accomplished individual to become chairman of Regulus’ Board.”
Papadopoulos retired as vice chairman of Cowen and Company in 2006 after six years with the firm, where he was an investment banker focused on the biotech and pharma sectors.
Prior to joining Cowen in 2000, Papadopoulos was an investment banker at PaineWebber Incorporated, most recently serving as chairman of PaineWebber Development, a PaineWebber subsidiary focusing on biotechnology.
Prior to that, he held positions in Equity Research covering the biotech industry at Drexel Burnham Lambert and Donaldson, Lufkin & Jenrette.
Papadopoulos is also deeply involved in the non-profit sector. He is a co-founder and chairman of Fondation Sante, a charitable foundation for scientific and educational purposes, and serves on the Board of Visitors at Duke University Medical Center.
Related Content
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the …
Alnylam shares positive results from phase 1 trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of …
FDA approves Exelixis’ cancer drug Cabometyx
The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) …
